Answers are grounded in this paper and cite their sources.
To investigate the clinicopathological characteristics and prognostic factors of breast cancer patients with initially positive internal mammary nodes (IMN) who received neoadjuvant therapy (NAT), and to identify the optimal radiotherapy dose for internal mammary nodal irradiation (IMNI). The data of 203 patients with initially positive IMN who received standardized NAT at the Fourth Hospital of Hebei Medical University between January 2013 and December 2022 were retrospectively analyzed to screen independent prognostic factors. Patients were stratified into a low-dose group (EQD2 ≤ 60 Gy) and a high-dose group (EQD2 > 60 Gy) according to the radiotherapy dose delivered to IMN (α/β = 4). Stabilized Inverse Probability Treatment Weighting (SIPW) was applied to balance baseline intergroup confounding variables. The primary survival endpoints included 5-year locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), and overall survival (OS). The median follow-up duration was 73 months. The 5-year LRFS, RFS, and OS rates of the entire cohort were 81.4%, 76.6%, and 84.6%, respectively. Multivariate Cox regression analysis demonstrated cT3–4 stage, Ki-67 > 20%, and lymph node ratio (LNR) > 20% served as independent adverse risk factors for poor RFS (all P < 0.05), whereas no independent prognostic factors associated with OS were identified (all P > 0.05). After SIPW adjustment, no statistically significant differences in 5-year LRFS, RFS, or OS were noted between the low-dose and high-dose radiotherapy groups (LRFS: 80.8% vs. 79.5%, P = 0.346; RFS: 75.8% vs. 74.4%, P = 0.291; OS: 85.9% vs. 80.8%, P = 0.149). Subgroup analyses demonstrated similar survival outcomes between radiotherapy subgroups, irrespective of whether clinical complete response (cCR) of internal mammary nodes (IMN) was achieved (all P > 0.05). For patients with axillary non-pCR, LRFS and OS were similar between the two dose groups (all P > 0.05), yet the high-dose group exhibited inferior RFS relative to the low-dose group ( P = 0.026). In patients with IMN non-cCR, the high-dose group presented numerical superiority in 5-year LRFS and RFS, particularly in patients with an IMN response rate ≤ 30%. cT3–4 stage, Ki-67 index > 20%, and LNR > 20% are independent adverse prognostic factors for patients with initially IMN-positive breast cancer after NAT. High-dose IMNI failed to significantly improve survival outcomes in the total study cohort. In the era of intensified modern systemic therapy, de-escalated radiotherapy for IMN may be a feasible strategy. However, caution should be exercised in managing patients with IMN non-cCR, especially those with an IMN response rate ≤ 30%. Further prospective clinical trials are required to validate our findings. Not applicable.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: